Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCOJIL)

• Drug Name: 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Drug Info
• Synonyms: CHEMBL50166; 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline; SCHEMBL6159581; ZINC26870; BDBM50127827

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 18326767
  TTD Drug ID: DMCOJIL

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Propericiazine	DME9JNL	Psychiatric disorder	6E8Z	Approved	[3]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[4]
Phendimetrazine	DM6TS1N	Obesity	5B81	Approved	[5]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[6]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[7]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[8]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[9]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[10]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[11]

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Hypertension	BA00-BA04	Approved	[12]
Armodafinil	DMGB035	Pediatric cancer	2A00-2F9Z	Approved	[13]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[14]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[15]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[16]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[17]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[18]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[6]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[19]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[20]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 1 (NMDAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[21]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[22]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[23]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[24]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[25]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[26]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[27]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[28]
Dizocilpine	DMMGYXR	Cerebrovascular ischaemia	8B1Z	Terminated	[29]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[30]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2B (NMDAR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[31]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[23]
CP-101,606	DMIU19E	Parkinson disease	8A00.0	Phase 2	[32]
CERC-301	DMSABRI	Major depressive disorder	6A70.3	Phase 2	[33]
RGH-896	DMCHZAN	Peripheral neuropathy	8C0Z	Phase 2	[34]
MIJ821	DMN45RI	Major depressive disorder	6A70.3	Phase 2	[35]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[24]
Neu-2000	DMNJTLC	Cardiac arrest	MC82	Phase 1	[36]
EVT100	DMAKWQD	Major depressive disorder	6A70.3	Phase 1	[37]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[25]

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Silodosin	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[38]
Naftopidil	DMQ8R4E	Hypertension	BA00-BA04	Approved	[38]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[39]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[40]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[41]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[42]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[6]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[20]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[20]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Inhibitor	[1]
Glutamate receptor ionotropic NMDA 1 (NMDAR1)	TTLD29N	NMDZ1_HUMAN	Inhibitor	[1]
Glutamate receptor ionotropic NMDA 2B (NMDAR2B)	TTN9D8E	NMDE2_HUMAN	Inhibitor	[1]

References

• [1] 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.
• [2] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [3] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [4] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [5] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [6] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [7] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [8] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [9] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [10] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [11] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [12] The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
• [13] Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
• [14] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [15] Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
• [16] Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
• [17] Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
• [18] The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
• [19] Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
• [20] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [21] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [22] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [23] 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
• [24] Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
• [25] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [26] Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
• [28] Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
• [29] Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
• [30] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [31] NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
• [32] NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
• [33] Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
• [34] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [35] Clinical pipeline report, company report or official report of Cadent Therapeutics.
• [36] Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
• [37] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [38] Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [40] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [41] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [42] Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.